Amyloid β is one of the pathological targets in Alzheimer's Disease, the design frame of clinical trials should based on the heterogenicities of AD. Further, as Prof. Murphy said, "Although it may not quite be time to give up on Aβ immunotherapy for treating Alzheimer’s disease, it would be foolish to ignore the continued failures of antiamyloid approaches". The question is:
When is the time to shift the aim of AD treatment from Aβ, or P-tau, to the right therapeutic target of the cognitive synapse network?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.